Elicio Therapeutics disclosed that its KRAS-mutation-driven pancreatic cancer vaccine ELI-002 7P failed to meet the primary endpoint in its randomized Phase 2 Amplify-7P study conducted in the adjuvant setting after standard locoregional therapy. The result pushed shares sharply lower as investors moved to recalibrate expectations for the program. The company said the intent-to-treat population did not achieve the prespecified disease-free survival endpoint, though it highlighted early signals from landmark analyses during active treatment and additional upside in DFS at three and six months. Even with the contextual discussion of those analyses, Elicio’s public communication underscored uncertainty around clinical durability. The outcome sets up a tougher financing and development decision point for a niche modality aimed at oncogene-directed immune activation, where endpoint maturity is critical for next-stage funding.